NCT01034826

Brief Summary

Impaired glucose tolerance is a metabolic state between normal glucose homeostasis and diabetes. Previously, prospective studies have shown higher progression rates from IGT to diabetes in other country. But There is no prospective-multicenter based reports in Korea. Therefore, the purpose of this study is to estimate the progression rates to impair glucose regulation and diabetes in the Korean population-based Korea national Diabetes program.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2007

Typical duration for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2007

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2009

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

December 17, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 18, 2009

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2010

Completed
Last Updated

June 9, 2010

Status Verified

December 1, 2009

Enrollment Period

2.8 years

First QC Date

December 17, 2009

Last Update Submit

June 8, 2010

Conditions

Impaired Glucose ToleranceDiabetes

Keywords

NGT, IGT, diabetes

Outcome Measures

Primary Outcomes (1)

  • fasting serum glucose, fasting plasma insulin,post prandial serum glucose, post prandial plasma insulin, hbA1c

    0.1.3.5 year

Study Arms (1)

life style modification

everyone in this study was advised about their life style, diet, exercise habits.

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients who vist the endocrinology department due to impaired fasting glucose or impaired glucose tolerance, or both.

You may qualify if:

  • fastic serum glucose \>100 and/or pp2 serum glucose \<200

You may not qualify if:

  • known diabetes
  • organ failure(For example, liver, kidney)
  • known malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Choi KM, Hwang SY, Hong HC, Yang SJ, Choi HY, Yoo HJ, Lee KW, Nam MS, Park YS, Woo JT, Kim YS, Choi DS, Youn BS, Baik SH. C1q/TNF-related protein-3 (CTRP-3) and pigment epithelium-derived factor (PEDF) concentrations in patients with type 2 diabetes and metabolic syndrome. Diabetes. 2012 Nov;61(11):2932-6. doi: 10.2337/db12-0217. Epub 2012 Jul 26.

    PMID: 22837306DERIVED

MeSH Terms

Conditions

Glucose IntoleranceDiabetes Mellitus

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 17, 2009

First Posted

December 18, 2009

Study Start

February 1, 2007

Primary Completion

December 1, 2009

Study Completion

May 1, 2010

Last Updated

June 9, 2010

Record last verified: 2009-12